MNG580
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.439
- OXIDATIVE_PHOSPHORYLATION+0.354
- P53_PATHWAY+0.273
- INFLAMMATORY_RESPONSE+0.239
- INTERFERON_GAMMA_RESPONSE+0.221
- INTERFERON_ALPHA_RESPONSE+0.211
- IL6_JAK_STAT3_SIGNALING+0.167
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.164
- IL2_STAT5_SIGNALING+0.156
- KRAS_SIGNALING_UP+0.153
Top 10 suppressed
- G2M_CHECKPOINT-0.523
- PROTEIN_SECRETION-0.475
- MITOTIC_SPINDLE-0.459
- E2F_TARGETS-0.405
- MTORC1_SIGNALING-0.342
- UNFOLDED_PROTEIN_RESPONSE-0.328
- ANDROGEN_RESPONSE-0.316
- MYC_TARGETS_V2-0.308
- HEDGEHOG_SIGNALING-0.276
- UV_RESPONSE_DN-0.275
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.875 |
| 2 | TCGA-E7-A519-01A-11R-A26T-07 | — | — | 0.846 |
| 3 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.839 |
| 4 | SRR5088872 | — | — | 0.830 |
| 5 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.827 |
| 6 | TCGA-OR-A5LN-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.825 |
| 7 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.820 |
| 8 | DRR168526 | — | — | 0.816 |
| 9 | TCGA-BA-A6DB-01A-11R-A30B-07 | — | — | 0.815 |
| 10 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.439 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.354 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.273 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.239 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.221 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.211 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.167 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.164 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.156 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.153 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.119 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.113 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.108 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.108 | Inavolisib | — uncovered |
| COMPLEMENT | 0.106 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.073 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.057 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.046 | Inavolisib | — uncovered |